Important to mention that this observationdid not prove to be a hindrance in our endeavor as tazemetostat (I) despite being a magnificently potent EZH2 inhibitor couldnot exert cell growth inhibitory potential against the GBM cell linesas per our preliminary screening results, some literature precedentsas well as the comparative analysis report of tazemetostat (I) vs hybrid scaffolds (1–10, Table 6). This evidence concerns the gene EZH2 and glioblastoma.